2022 Patients Pharmacology Safety 
pharmaphorum
AUGUST 16, 2022
The highly anticipated Lipid Nanoparticle Immunogenicity & Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology , immunogenicity , bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.
European Pharmaceutical Review
JULY 13, 2023
1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 2, 2023
3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. 1,2 In the EU, an estimated 2.7
pharmaphorum
JANUARY 17, 2023
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics.
pharmaphorum
DECEMBER 22, 2022
Also tipped as a blockbuster, Zeposia has been gathering momentum with sales doubling to $171 million in the first nine months of 2022. Pfizer reckons the pharmacology of etrasimod – including its engagement with S1P 1, 4 and 5 receptor subtypes – differentiates the drug from its rival, which binds mainly to subtypes 1 and 5.
Legacy MEDSearch
AUGUST 25, 2022
The PiCSO-AMI-II multicenter, randomized trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI) presenting with TIMI flow 0, 1, and 2 within 12 hours of symptom onset. The primary safety endpoint is a performance goal for device and procedure related adverse events at 30 days.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
52 
Let's personalize your content